Zura Bio Ltd — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Zura Bio Ltd filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($68.65M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($52.40M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($60.36M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($25.74M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $6.85M | Mar 28, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($75.25M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($55.19M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($62.64M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($27.16M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($888.5K) | Mar 28, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.08M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $24.40M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $44.00M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $23.69M | Mar 28, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($64.82M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($28.08M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($15.05M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($1.20M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.10M) | Mar 28, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.0K | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $75.0K | Mar 19, 2026 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.95M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $179.53M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $100.84M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $5.26M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $140.55M | Mar 28, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.41M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $19.51M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $21.29M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $14.82M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $10.35M | Mar 28, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $101.54M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $146.82M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $59.33M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($32.06M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($9.18M) | Mar 28, 2023 |
| FY2022 | Mar 9, 2021 | $0 | Mar 28, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($224.55M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($155.90M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($103.49M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($32.06M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($9.18M) | Mar 28, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.41M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $176.50M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $99.81M | Mar 25, 2025 |
| FY2022 | Dec 31, 2022 | $13.8K | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $729.2K | Mar 28, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (141) | Mar 28, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (141) | Mar 28, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 73.68M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 65.30M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 43.59M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 279,720 | Mar 28, 2024 |